Medical Condition

follicular lymphoma

Total Trials

12

Recruiting Now

12

Trial Phases

Phase 2, Phase 1, Phase 2, Phase 1

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — follicular lymphoma Clinical Trials

How many clinical trials are currently recruiting for follicular lymphoma?

ClinicalMetric currently tracks 12 actively recruiting clinical trials for follicular lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 12. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for follicular lymphoma?

follicular lymphoma research spans Phase 1 (5 trials), Phase 2 (7 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a follicular lymphoma clinical trial?

Eligibility criteria for follicular lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

Masonic Cancer Center, University of Minnesota 2 trials

John Lister 1 trial

New York Medical College 1 trial

University Hospital Heidelberg 1 trial

Iksuda Therapeutics Ltd. 1 trial

Recruiting Clinical Trials

NCT05281809 Phase 2

Recruiting

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

NCT04491370 Phase 1, Phase 2

Recruiting

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

New York Medical College

View Trial →

NCT03676504 Phase 1, Phase 2

Recruiting

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

University Hospital Heidelberg

View Trial →

NCT05365659 Phase 1

Recruiting

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

Enrollment

140 pts

Location

United States, Austr...

Sponsor

Iksuda Therapeutics Ltd.

View Trial →

NCT06704555 Phase 2

Recruiting

Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma

Tianjin Medical University Can...

View Trial →

NCT06792825 Phase 2

Recruiting

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

Masonic Cancer Center, Univers...

View Trial →

NCT03314974 Phase 2

Recruiting

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Masonic Cancer Center, Univers...

View Trial →

NCT04998669 Phase 2

Recruiting

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Juan P. Alderuccio, MD

View Trial →

NCT05512390 Phase 1

Recruiting

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Enrollment

154 pts

Location

United States, Austr...

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Enrollment

790 pts

Location

Austria, Belgium, Fr...

Sponsor

The Lymphoma Academic Research...

View Trial →

NCT03375619

Recruiting

Long-term Follow-up Study of Patients Receiving CAR-T Cells

Medical College of Wisconsin

View Trial →

NCT06026319 Phase 1

Recruiting

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Marcela V. Maus, M.D.,Ph.D.

View Trial →

Related Conditions

diffuse large b cell lymphoma (7) mantle cell lymphoma (7) chronic lymphocytic leukemia (5) marginal zone lymphoma (4) b cell lymphoma (3) burkitt lymphoma (3) lymphoplasmacytic lymphoma (2) multiple myeloma (2) b acute lymphoblastic leukemia (1) transformed lymphoma (1) transformed non hodgkin lymphoma (1) richter syndrome (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology